Tazobactam (Zobact Iv)
Tazobactam
Austell Pharmaceuticals (Pty) Ltd
Every registration of this product has been cancelled.
Registration
- Applicant
- Austell Pharmaceuticals (Pty) Ltd
- Registrations
- 1
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Zobact iv 4,5 g EACH VIAL CONTAINS: PIPERACILLIN SODIUM EQUIVALENT TO PIPERACILLIN 4,0 g TAZOBACTAM SODIUM EQUIVALENT TO TAZOBACTAM 0,5 g | 4,5 g | 50074250/20.1.1/0742 | Cancelled | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Piperacillin
- anhydrous.
Consolidated Schedules 06 July 2026, line 7570
S4: Tazobactam
Consolidated Schedules 06 July 2026, line 8106
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
(2S,3S,5R)-3-Methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4lambda6-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
Drag to rotate. Structure from PubChem CID 123630.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.